Novo Nordisk reports strong financial, social and environmental performance for 2010 Novo Nordisk, the world leader in diabetes care, has released its seventh annual integrated report with 2010 results. The company’s achievements for the year include solid sales growth, progress in clinical development programmes, healthcare system capacity building, and reductions in resource consumption and CO2 emissions.

During 2010, Novo Nordisk:

• Increased sales by 13% (in local currencies) and by 19% in Danish kroner to DKK 60,776 million compared to 2009.
• Maintained global leadership in diabetes care with 51% of the total insulin market measured by volume.
• Trained or sponsored training for more than 350,000 healthcare providers to improve diabetes care globally.
• Expanded support for healthcare capacity building in developing countries by donating 69 million Danish kroner to the World Diabetes Foundation and 15 million kroner to the Novo Nordisk Haemophilia Foundation.
• Reduced CO2 emissions from production by 35% compared to 2009.

In the absence of global standards for inclusive reporting, the report was prepared in respect of international standards for mandatory and voluntary reporting:

• International Financial Reporting Standards (IFRS)
• AA1000 (2008) Framework
• Global Reporting Initiative (G3) Sustainability Reporting Guidelines
• UN Global Compact
• US Sarbanes-Oxley Act

Novo Nordisk is in compliance with US Sarbanes-Oxley Act section 404, which requires detailed documentation of the design and operation of financial reporting processes. Novo Nordisk's board has requested that the company's non-financial reporting be subject to the same types of internal control procedures required for financial data, and the company has been working towards this objective since 2008.

Novo Nordisk manages its business using the Triple Bottom Line principle to ensure that decision-making balances profitability with societal interests. The company's integrated reporting seeks to meet the information needs of all stakeholders. The company reports additional information for specific stakeholder groups at annualreport2010.novonordisk.com. Novo Nordisk values feedback and welcomes questions or comments about its reporting and performance at annualreport@novonordisk.com.

About Novo Nordisk
Novo Nordisk is a global healthcare company with nearly 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs more than 30,000 employees in 74 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO).

Novo Nordisk strives to conduct its activities in a financially, environmentally and socially responsible way. The strategic commitment to corporate sustainability has brought the company onto centre stage as a leading player in today's business environment, recognised for its integrated reporting, stakeholder engagement and consistently high sustainability performance. Novo Nordisk is listed in the 2010/2011 Dow Jones Sustainability Indices with a gold class rating. For more information, visit novonordisk.com/sustainability.

Novo Nordisk

Novo Nordisk

Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. We believe that a healthy economy, environment and society are fundamental to long-term value creation. This is why we manage our business in accordance with the Triple Bottom Line business principle and consider the financial, environmental and social impact of our business decisions. The strategic commitment to corporate sustainability has brought the company onto centre stage as a leading player in today's business environment, recognised for its integrated reporting, stakeholder engagement and consistently high sustainability performance.

More from Novo Nordisk